Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized active-controlled trial of Albuferon plus ribavirin in chronic hepatitis C genotype 1
2005-000867-24Phase 2Completed
- Sponsor
- GSK
- Start
- Mar 2005
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of albinterferon alfa-2b in hepatitis C virus infection (2 arms), sponsored by GSK. Primary endpoint: Sustained virologic response (SVR). Started Mar 2005; status: completed.
02
Drugs
albinterferon alfa-2b
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2005-000867-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000867-24.